XML 72 R44.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Commitments and Contingencies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Commitments and Contingencies [Abstart] |
Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions | The aggregate amounts of the contingent milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as of December 31, 2023 are below:
|  | Amount |
Drug molecules: up to the conditions and milestones of |  |  |
Preclinical to IND filing |  | $ | 132,564 |
From entering phase 1 to before first commercial sale |  |  | 17,376,410 |
First commercial sale |  |  | 11,882,051 |
Net sales amount more than certain threshold in a year |  |  | 44,769,231 |
Subtotal |  | $ | 74,160,256 |
Diagnostics technology: up to the conditions and milestones of |  |  |  |
Before FDA approval |  | $ | 208,656 |
|  | $ | 74,368,912 |

X
- Definition Tabular disclosure of milestone payments are to be made upon achievements of certain conditions. + References No definition available. + Details
Name: | apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock
Namespace Prefix: | apm_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration